Introduction {#Sec1}
============

Severe acute respiratory syndrome coronavirus (SARS-CoV) belongs to the genus *Betacoronavirus* of the family *Coronaviridae* and has a plus-strand RNA genome of approximately 29.7 kb with a 5' cap-structure and a 3' poly(A) tail \[[@CR18]\]. The SARS-CoV genome has 14 open reading frames (ORFs) flanked by 5' and 3' untranslated regions (UTRs), which are essential *cis*-acting elements required for viral replication \[[@CR29]\]. The 5' two-thirds of the viral genome contains two large ORFs, 1a and 1b, the latter of which is expressed by ribosomal frameshifting near the 3' end of ORF1a \[[@CR1], [@CR23]\]. The two large polyproteins, pp1a, encoded by ORF1a, and pp1ab encoded by ORF1a and ORF1b, are processed by two viral proteases to generate a total of 16 nonstructural proteins (nsps), most of which likely serve as RNA replicase components \[[@CR29], [@CR35]\]. The nsp12, which is the first protein encoded by ORF1b, has common viral RNA-dependent RNA polymerase (RdRp) motifs and is thus the catalytic core of the RNA replicase \[[@CR39]\].

RNA genome replication is a crucial step in SARS-CoV propagation and is mediated by the RNA replicase, which has been proposed to be comprised of viral nsps and host proteins. The SARS-CoV replicase complex transcribes the full-length plus-strand viral genome and its complementary minus-strand genomic RNA template. In addition, the replication complex transcribes a set of 3'-coterminal nested subgenomic mRNAs with a 5' leader sequence derived from the 5' end of the genome and the corresponding minus-strand subgenomic RNAs by discontinuous RNA transcription \[[@CR26], [@CR29]\]. During synthesis of the viral genome and its subgenomes, nsp12, alone or with the help of viral and/or cellular proteins, is thought to initiate RNA synthesis from the 3' ends of the viral genome and subgenomes in both the plus and minus senses \[[@CR37]\]. Correct initiation of RNA synthesis is essential for maintenance of the integrity of viral genomes. RNA viruses use two principally different mechanisms by which RNA synthesis can be initiated: *de novo* initiation and primer-dependent initiation \[[@CR12]\]. During *de novo* initiation, the starting nucleotide provides the 3' hydroxyl group for the addition of the next nucleotide. In contrast, primer-dependent initiation requires the use of a separate oligonucleotide or protein primer to provide the hydroxyl nucleophile. The mechanisms of RNA synthesis initiation for SARS-CoV have not been well characterized. In particular, the details of subgenomic RNA synthesis remain unknown \[[@CR19]\].

An *in vitro* RdRp assay system for SARS-CoV would be useful for studying the mechanisms of viral RNA replication, screening for RdRp inhibitors, and identifying target sites of nucleic-acid-based antiviral agents through mapping of important *cis*-acting elements. Further, it would be an important tool for determining the mode of RNA synthesis initiation to provide important mechanistic insight into the SARS-CoV replication cycle \[[@CR19]\]. Previously, the RdRp activity of SARS-CoV nsp12 was demonstrated using non-viral RNA templates \[[@CR4], [@CR33]\]. An RdRp assay system using an enzymatically active nsp12 accepting exogenous viral genome-derived RNA templates would enable us to characterize RNA synthesis initiation mechanisms and to initiate exploration of the mechanisms involved in subgenomic RNA synthesis. However, previous studies did not investigate whether nsp12 uses the 3'-end RNA regions of the viral genome and its complementary minus-strand RNA template.

In the present study, we cloned and expressed a full-length recombinant SARS-CoV nsp12. With the purified recombinant nsp12, we established an *in vitro* RdRp assay system and demonstrated that nsp12 was capable of *de novo* RNA synthesis initiation using viral RNA templates corresponding to the 3' ends of the plus and minus strands of the SARS-CoV genome. Furthermore, we mapped the minimal *cis*-acting regions required for initiation of plus- and minus-strand viral RNA synthesis.

Material and methods {#Sec2}
====================

Construction of the recombinant SARS-CoV nsp12 expression vector {#Sec3}
----------------------------------------------------------------

Total RNA from Vero cells infected with the SARS-CoV Urbani strain (GenBank accession number: AY278741) was isolated using TRIzol Reagent (Invitrogen). The RNA was reverse-transcribed using ImProm-II reverse transcriptase (Promega) and the reverse primer Spol_R (5'-CG[GGATCC]{.ul}TACTGCAAGACTGTATGTGG-3'; *Bam*HI site underlined). The full-length nsp12 coding sequence was amplified by PCR with Pfu polymerase (Takara), using the forward primer Spol_F (5'-GC[TCTAGA]{.ul}ATGCAGTCTGCGGATGCATCAACGTTCTTGAATCGGGTTTGCGGTGTAAGTGCAGCCCGT-3'; *Xba*I site underlined) and the Spol_R primer. The PCR product was digested with *Xba*I and *Bam*HI and ligated into *Nhe*I- and *Bam*HI-digested pTrcHisB (Invitrogen) vector to construct the nsp12-expression plasmid pTrcSARSnsp12_FL. The coding sequence of the unique domain (S~4370~-E~4739~) of nsp12 was amplified by PCR with the Spol_F and the SpolUnique_R (5'-CG[GGATCC]{.ul}CTATTCCTTGAAACTGAGACGCGAG-3'; *Bam*HI site underlined) primers. The PCR product was ligated into pTrcHisB, generating the construct designated pSARSnsp12_UD. The SDD motif in the nsp12 active site was mutated to SAA by bridged PCR using oligonucleotides containing the target mutations as described previously \[[@CR21]\].

Expression and purification of recombinant SARS-CoV nsp12 {#Sec4}
---------------------------------------------------------

SARS-CoV nsp12 was expressed in *E. coli* TOP10 cells (Invitrogen). Cells transformed with pTrcSARSnsp12_FL were grown at 37 °C to an optical density at 600 nm of 0.6-0.8. Expression of nsp12 was induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside for 20 h at 18 °C. SARS-CoV nsp12 was purified by metal affinity chromatography using Ni-nitrilotriacetic acid-agarose (QIAGEN) resin as described previously \[[@CR13]\]. SARS-CoV nsp12-containing fractions were collected, dialyzed against buffer A (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM DTT, 10 % glycerol), and then applied to a Q-Sepharose column (Amersham Biosciences). Bound proteins were eluted with a step-gradient of NaCl from 50 mM to 800 mM. Fractions containing nsp12 were further purified using a Hiload 16/60 Superdex 200 column (Amersham Pharmacia Biotech) as described previously \[[@CR13]\]. The SARS-CoV nsp12-containing fractions were mixed with cold glycerol (10 % final concentration) and stored at −80 °C.

Western blot analysis {#Sec5}
---------------------

Purified SARS-CoV nsp12 and its derivatives were separated by 10 % SDS-PAGE and transferred to a nitrocellulose membrane (Hybond-ECL; GE Healthcare Life Sciences) for probing with an anti-penta (His)-tag antibody (Qiagen) as described previously \[[@CR13]\].

RNA template preparation {#Sec6}
------------------------

The DNA templates for *in vitro* RNA transcription were obtained by RT-PCR amplification using the total RNA extracted from SARS-CoV infected cells. The DNA template for the 3'-UTR of the SARS-CoV genome was amplified with the reverse primer 3'-UTR_R (5'-GTCATTCTCCTAAGAAGCT-3') and the forward primer 3'UTR339_F (5'-[TAATACGACTCACTATA]{.ul} ***G***GCCCCATGTGATTTTAATAGC-3'; the T7 promoter sequence is underlined and the extra G nucleotide in italics was added for efficient transcription by T7 RNA polymerase) using the cDNA synthesized with the reverse primer 3'-UTR_R. The DNA template for the region complementary to the SARS-CoV 5'-UTR genome (c5'-UTR) was amplified with the reverse primer 5'-UTR_R (5'-[TAATACGACTCACTATA]{.ul} ***GG***CTTACCTTTCGGTCACAC-3'; the T7 promoter and extra G nucleotides are indicated, as described above) and the forward primer 5'UTR_F (5'-ATATTAGGTTTTTACCTAC-3') using the cDNA synthesized with the reverse primer 5'-UTR_R. DNA templates for deletion derivatives of the 3'-UTR and c5'-UTR were similarly amplified with appropriate sets of primers. The resulting PCR products containing the T7 promoter were used directly for *in vitro* transcription using a T7 MEGAscript kit (Ambion) as described previously \[[@CR1]\]. DNA templates for the 3'-UTR containing the poly(A) tail was amplified by RT-PCR with the reverse primer 3'UTRBsaI_R (5'-[GGTCTCT↓TTTTT]{.ul}TTTTTTTTTTTT-3'; a *Bsa*I site is underlined, and the digestion site is indicated by the arrow) and the forward primer 3'-UTR339_F. PCR products were cloned into pCR2.1TOPO vector (Invitrogen). The resulting plasmids with inserts containing different lengths of poly(A) tail (14, 17, 19, and 33 nt) were isolated by sequence analysis. These plasmids, linearized by *Bsa*I digestion, were then used for *in vitro* transcription to prepare the 3'-UTR templates containing various lengths of poly(A) tail (13, 16, 18, and 32 nt).

Prediction of RNA secondary structure {#Sec7}
-------------------------------------

RNA secondary structures were predicted with the RNA mfold program \[[@CR11]\]. The structure drawings were edited and annotated using the RnaViz 2 program \[[@CR6]\].

RdRp assay {#Sec8}
----------

The *in vitro* RdRp assay was performed with 3 pmol of recombinant SARS-CoV nsp12 in a total volume of 25 μl RdRp reaction buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM MnCl~2~ unless otherwise specified, 1 mM DTT, 10 % glycerol, 20 units of RNase inhibitor \[Promega\]) containing 1 μg of each of the homopolymeric RNA templates, 5 μM complementary rNTP, 10 pmol 20-mer ribo-oligonucleotide (rN)~20~ primer, and 5 μCi \[α-^32^P\] of each complementary rNTP (3,000 Ci/mmol, Amersham Pharmacia Biotech). The reaction mixture was incubated for 2 h at 32 °C. For RdRp reactions with viral RNA templates, 500 ng RNA template was added to the reaction mixture as described above, except that a mixture of cold ribonucleotides (500 μM each ATP, CTP, and GTP, and 5 μM UTP) was included in the reaction with 5 μCi \[α-^32^P\] UTP. After the RdRp reaction, reaction products were processed and resolved on denaturing 5 % polyacrylamide gels containing 8 M urea as described previously \[[@CR13]\]. After electrophoresis, the gels were stained with ethidium bromide to locate the template positions, photographed, dried, and then exposed to X-ray film for autoradiography.

Protein identification by tandem mass spectrometry (MS/MS) {#Sec9}
----------------------------------------------------------

Gel bands were excised and subjected to in-gel trypsin digestion as described previously \[[@CR28]\]. Digested samples were desalted using a homemade C~18~ nano-column. MS/MS was performed using nano-ESI on a Q-TOF2 mass spectrometer (AB Sciex Instruments). To identify the peptides, all MS/MS spectra recorded for tryptic peptides were searched against protein sequences from NCBInr and EST databases using the MASCOT search program (<http://www.matrixscience.com>).

Results {#Sec10}
=======

Expression and purification of a full-length recombinant SARS-CoV nsp12 {#Sec11}
-----------------------------------------------------------------------

The gene encoding the full-length nsp12 was amplified by RT-PCR using the total RNA from Vero cells infected with the SARS-CoV Urbani strain (Fig. [1](#Fig1){ref-type="fig"}A). We amplified the gene using a forward primer to generate an nsp12 gene that was in frame with the upstream ORF1a translation, resulting in an amino acid sequence that was the same at the N-terminus of SARS-CoV nsp12 (SADASTFLN). T7 RNA polymerase was previously shown to have an RNA-labeling activity *in vitro* on some RNAs through intra- or intermolecular priming \[[@CR3]\]. Thus, to avoid potential contamination of T7 RNA polymerase, the amplified gene was expressed using the *E. coli* expression vector pTrcHisB, in which gene expression is controlled by a *trc* chimeric promoter. As shown in Fig. [1](#Fig1){ref-type="fig"}A, the recombinant nsp12 expressed from the resulting vector is expected to have extra amino acids at the N-terminus, which are introduced during the cloning procedure. A (His)~6~-tag was also added to the N-terminal part of nsp12 for convenient purification using a Ni-affinity chromatography column.Fig. 1**Purification of full-length SARS-CoV nsp12 expressed in** ***E. coli.*** (**A**) Schematic diagram of a full-length SARS-CoV nsp12. The unique domain, the catalytic domain, and the conserved RdRp active-site residues of the nsp12 are indicated. The deduced N-terminal sequences of the indicated nsp12 protein are shown. (**B**-**D**) The nsp12 protein was expressed in *E. coli* and purified by affinity chromatography using an Ni-NTA agarose column (**B**), anion-exchange chromatography using a Q-Sepharose column (**C**), and GFC using a Superdex 200 column (**D**). SARS-CoV nsp12 bound to an Ni-NTA agarose and a Q-Sepharose column were eluted by increasing concentrations of imidazole and NaCl, respectively. Eluted proteins and fractions collected from the Superdex 200 column were separated by 10 % SDS-PAGE and stained with Coomassie blue. Arrowheads indicate the position of SARS-CoV nsp12. In panel (**D**), proteins identified by MS/MS analysis are shown. (**E**) The final purified recombinant nsp12 (2 μg) was resolved by SDS-PAGE and visualized by Coomassie blue staining

Recombinant nsp12 was expressed for 20 h at 18 °C to obtain soluble, intact protein, which was subsequently purified by nickel affinity chromatography. As shown in Fig. [1](#Fig1){ref-type="fig"}B, full-length nsp12 was enriched in the imidazole-elution fractions. Eluted proteins were then applied to a Q-Sepharose column to obtain fractions containing two major proteins (105- and 26-kDa proteins) by eluting bound proteins with approximately 800 mM NaCl (Fig. [1](#Fig1){ref-type="fig"}C, lane 6). The eluted proteins were further purified by two rounds of GFC. Size fractionation successfully separated kDa nsp12 that was truncated by approximately 40 (Fig. [1](#Fig1){ref-type="fig"}D, see fractions 19-27) and host proteins (*E. coli* L-glutamine: D-fructose-6-phosphate aminotransferase, glycerol dehydrogenase, and FKBP-type peptidyl-prolyl *cis-trans* isomerase), which were identified by MS/MS analysis, from the full-length, intact nsp12. Fractions enriched for nsp12 were combined and subjected to a second round of GFC to obtain \>95 % pure nsp12 protein (Fig. [1](#Fig1){ref-type="fig"}E). The purified protein could be detected using an anti-penta histidine antibody (data not shown), and its identity was confirmed by MS/MS analysis. Small aliquots of the nsp12-containing fractions were stored at −80 °C for at least three months without losing enzyme activity.

Nsp12 has primer- and Mn^2+^-dependent RdRp activity {#Sec12}
----------------------------------------------------

Since divalent metal ions are essential cofactors for viral RdRps \[[@CR13]\], we initially tested the RdRp activity of purified nsp12 in the presence of either Mg^2+^ or Mn^2+^. The RdRp assay was performed with a poly(A) RNA template in the absence and presence of the primer oligo(U)~20~. As shown in Fig. [2](#Fig2){ref-type="fig"}A, nsp12 exhibited primer-dependent RdRp activity that was strictly dependent on Mn^2+^ for RNA synthesis. Mg^2+^ could not replace Mn^2+^ (2 mM; Fig. [2](#Fig2){ref-type="fig"}B), even at concentrations up to 10 mM (data not shown). Using the two viral-genome-derived RNA templates representing parts of the 3'-UTRs of the plus and minus strands of the viral genome, namely 3'-UTR339 + 16A and c5'-UTR119 (see the schematic diagrams of these RNA templates shown in Fig. [4](#Fig4){ref-type="fig"}), we consistently observed Mn^2+^-dependent RdRp activity (Fig. [2](#Fig2){ref-type="fig"}C). This Mn^2+^-dependent RdRp activity was also observed using a poly(C) template (Fig. [3](#Fig3){ref-type="fig"}B). The optimal Mn^2+^ concentration for nsp12 activity was 2 mM (Fig. [2](#Fig2){ref-type="fig"}D). The temperature and pH for optimal SARS-CoV nsp12 activity were determined to be 32 °C and pH 7.5, respectively (Fig. [2](#Fig2){ref-type="fig"}E and F). Potassium (K^+^) ions exhibited an inhibitory effect on enzyme activity at concentrations higher than 50 mM (Fig. [2](#Fig2){ref-type="fig"}G).Fig. 2**Primer- and Mn** ^**2+**^ **-dependent RNA synthesis by nsp12.** RdRp assays were performed with a homopolymeric poly(A) RNA template in the presence (+) or absence (−) of the 20-nt complementary ribonucleotide primer U~20~ (**A** and**B**, as indicated;**D**-**G**, in the presence of U~20~) or with the viral-genome-derived RNA templates (**C**, see schematic diagrams of the RNA templates in Fig. [4](#Fig4){ref-type="fig"} **A** and**D**). The reactions were carried out in the presence of 2 mM Mn^2+^ (**A** and**E**-**G**), 2 mM Mg^2+^ or Mn^2+^ (**B**-**C**), or increasing concentrations of Mn^2+^ (**D**). Radioisotope-labeled RNA products were resolved on an 8 M urea-5 % polyacrylamide gel before drying and being exposed to x-ray film for autoradiography. In (**D**-**G**), the relative RdRp activity of nsp12 is presented as the percentage of that obtained under each optimal condition Fig. 3**Primer dependence of nsp12 in RNA synthesis initiation from homopolymeric RNA templates.** (**A**) RdRp assays were performed using the indicated homopolymeric RNA templates in the absence (−) or presence (+) of 20-mer complementary ribonucleotide primer. Mn^2+^ (2 mM) was used as the metal cofactor. The amount of ^32^P-GMP incorporated in the reaction with the poly(C)/(rG)~20~ template was measured to be \~5 × 10^4^ cpm. (**B**) RdRp assays were performed with a poly(C) template in the presence of Mg^2+^ or Mn^2+^. (**C**) RdRp activities of wild-type nsp12, a mutant nsp12 carrying a SDD-to-SAA substitution \[nsp12(SAA)\], and the unique domain of nsp12 (nsp12-unique domain) were tested with a poly(C) template in the absence of the (rG)~20~ primer. (**D**) RdRp assays with a poly(C) template were carried out in the absence (−) or presence of actinomycin D (20 μg/ml) or rifampicin (20 μg/ml). RNA products were analyzed as in Fig. [2](#Fig2){ref-type="fig"}

RdRp activity of nsp12 on homopolymeric RNA templates {#Sec13}
-----------------------------------------------------

To investigate the template preference of the recombinant SARS-CoV nsp12, we performed RdRp assays with four different homopolymeric RNA templates in the absence or presence of 20-mer complementary ribonucleotide primers. Interestingly, we found that homopolymeric pyrimidine RNA templates \[poly(C) and poly(U)\] served as better templates than homopolymeric purine RNA templates \[poly(A) and poly(G)\] (Fig. [3](#Fig3){ref-type="fig"}A). The polymerase activity was highest with the poly(C) template, and initiation of RNA synthesis occurred in the absence of a complementary (rG)~20~ primer, although addition of the primer increased the levels of RNA products (compare lanes 3 and 4). A similar increase in the amount of labeled RNA product was observed using a poly(U) template with an (rA)~20~ primer (lanes 7 and 8). In contrast, a low but detectable amount of RNA product was produced from the homopolymeric purine RNA templates only in the presence of complementary primers. Collectively, our results demonstrate that SARS-CoV nsp12 has both primer-dependent and primer-independent RNA synthesis activity, depending on the type of RNA template used.

The catalytic domain of SARS-CoV nsp12 is composed of finger, palm, and thumb subdomains, with a conserved SDD motif located in the active site of the palm subdomain (Fig. [1](#Fig1){ref-type="fig"}A) \[[@CR39]\]. To prove that the RdRp activity of nsp12 is due to its own enzymatic activity, we mutated the SDD~759-761~ motif to SAA to inactivate the enzyme. As shown in Fig. [3](#Fig3){ref-type="fig"}C, while wild-type nsp12 had robust RdRp activity on a poly(C) template (lane 1), the SAA mutation completely abolished the polymerase activity (lane 2). SARS-CoV nsp12 has a unique domain encompassing the N-terminal 370 amino acids, which is not present in most other plus-strand RNA virus RdRps, and the functional importance of this domain has not been determined \[[@CR29], [@CR39]\]. We expressed and purified a recombinant form of the unique domain and determined whether it had RNA-labeling activity. Using the *in vitro* RdRp assay with a poly(C) template, we found that the unique domain did not have RNA polymerase activity (Fig. [3](#Fig3){ref-type="fig"}C, lane 3). We also attempted to express the nsp12 catalytic domain (amino acids 371-932), but we could not get soluble recombinant proteins (data not shown). Lastly, the SARS-CoV RdRp activity was not significantly inhibited by either actinomycin D (20 μg/ml) or rifampicin (20 μg/ml) (Fig. [3](#Fig3){ref-type="fig"}D), indicating that the RdRp activity of nsp12 was not attributable to contamination by bacterial DNA-dependent RNA polymerases.

Mapping of minimal cis-acting signals required for viral RNA synthesis initiation {#Sec14}
---------------------------------------------------------------------------------

It has been reported that the poly(A) tail is an important *cis*-acting element for coronavirus replication \[[@CR30]\]. We sought to determine whether a poly(A) tail is required for *in vitro* minus-strand viral RNA synthesis. The 339-nt-long, full-length SARS-CoV 3'-UTR template lacking the poly(A) tail (Fig. [4](#Fig4){ref-type="fig"}A) and the 3'-UTR templates possessing different lengths of a poly(A) tail (13-32 polyadenylates) were prepared by *in vitro* transcription and used as templates for RdRp reactions. The recombinant nsp12 was able to copy the 3'-UTR template lacking the poly(A) tail in the absence of a primer (Fig. [4](#Fig4){ref-type="fig"}B, lane 1). Furthermore, the 3'-UTR RNA templates with 13-16 adenylates were used as efficiently as the 3'-UTR lacking the poly(A) tail (compare lane 1 with lanes 2 and 3). However, there was an incremental decrease in the amounts of RNA product when a poly(A) tail longer than 16 nt was added to the template (lanes 4 and 5). Having found that the 3'-UTR upstream of the poly(A) tail is critical for viral minus-strand RNA synthesis, we mapped the minimal *cis*-acting RNA element within the 3'-UTR by RdRp assays with serial deletion derivatives of the 3'-UTR template lacking the poly(A) tail. As shown in Fig. [4](#Fig4){ref-type="fig"}C, nsp12 was able to synthesize template-size labeled RNA products in a primer-independent manner, suggesting that a 36-nt sequence and/or a secondary structure in the 3'-UTR is a minimal RNA region recognized by nsp12 for *de novo* RNA synthesis initiation *in vitro*.Fig. 4**Mapping of minimal RNA domains required for initiation of plus-strand and minus-strand viral RNA synthesis.** (**A**) Schematic representation of 3'-UTR RNA templates without or with various lengths (13-32 nt) of polyadenylate and deletion derivatives of the 3'-UTR lacking a poly(A) tail (3'-UTR339∆A). The most stable secondary structure of 3'-UTR36∆A predicted by the Mfold program \[[@CR40]\] is shown. (**B**) RdRp assays were performed with the indicated RNA templates. The numbers following the +sign of the series of 3'-UTR339∆A RNA templates indicate the length of the poly(A) tail. Radioisotope-labeled RNA products were resolved on a medium-size 8 M urea-8 % acrylamide gel (20 cm × 20 cm) and subjected to autoradiography. (**C**) Minimal *cis*-acting RNA elements required for minus-strand RNA synthesis were mapped by RdRp assays using the indicated deletion derivatives of the 3'-UTR36∆A. The numbers following the letters "3'-UTR" indicate the corresponding size of each template. RNA products were analyzed as in (**B**). Template positions are indicated with arrowheads. (**D**) Deletion derivatives of c5'-UTR RNA templates are depicted on schematic diagrams. The most stable secondary structure of the c5'-UTR 38-nt RNA template predicted by the Mfold program is shown. The numbers following the letters "c5'-UTR" represent the corresponding size of each template. (**E**) Minimal *cis*-acting RNA elements required for plus-strand RNA synthesis were mapped by RdRp assays using the indicated RNA templates. Template positions are indicated by arrowheads

Like the 3'-UTR of the plus-strand viral genome, the 3'-end region of the minus-strand RNA template is also important for the initiation of viral RNA genome synthesis \[[@CR21], [@CR25]\]. To map the minimal region recognized by SARS-CoV RdRp, various RNA templates (Fig. [4](#Fig4){ref-type="fig"}D) representing the complementary sequences of the 5'-UTR of the SARS-CoV genome (c5'-UTR) were tested for their template activities in the *in vitro* RdRp assay. The nsp12 was able to initiate RNA synthesis with as little as 37 nt of RNA from the 3' end of the c5'-UTR (Fig. [4](#Fig4){ref-type="fig"}E, lane 5). Thus, a 36-nt sequence from the 3'-UTR and a 37-nt sequence from the c5'-UTR, which were predicted to form stable stem-loop structures (Fig. [4](#Fig4){ref-type="fig"}A and D), seem to be the minimal *cis*-acting RNA elements required for nsp12 to initiate RNA synthesis. Together, the data suggested that nsp12 might be able to initiate RNA synthesis from either a double-stranded stem region (Fig. [4](#Fig4){ref-type="fig"}A) or a single-stranded region (Fig. [4](#Fig4){ref-type="fig"}D). Furthermore, these results clearly demonstrated that recombinant SARS-CoV nsp12 was able to initiate both minus- and plus-strand viral RNA synthesis *in vitro* without the aid of other viral and cellular proteins.

Discussion {#Sec15}
==========

In this study, we characterized the biochemical properties of a full-length SARS-CoV nsp12 that can initiate RNA synthesis *de novo* from the 3' ends of both the plus and minus strands of the SARS-CoV genome. The nsp12 required a minimal region of less than 40 nt at the termini of the viral genome and its complementary minus-strand RNA for initiation of RNA synthesis. Our data also demonstrated that the poly(A) tail at the 3' end of viral genome plays a regulatory role in initiation of RNA synthesis during minus-strand RNA synthesis.

Previously, SARS-CoV *in vitro* RdRp assay systems were established using a replication/transcription complex (RTC) \[[@CR38]\] or using recombinant nsp12 \[[@CR4], [@CR34]\]. The RTC, which was isolated from double-membrane vesicles formed in SARS-CoV-infected cells, displayed an RdRp activity using endogenous RTC-associated viral RNA templates. However, it was not determined whether or not the SARS-CoV RTC could utilize exogenous RNA templates. Furthermore, the RdRp activity was dependent on an as-yet-unidentified host factor(s) present in the cytoplasmic soluble fraction. In contrast to the results observed with the RTC, a glutathione S-transferase (GST)*-*fused SARS-CoV RdRp showed primer-dependent RdRp activity on a poly(A) RNA template \[[@CR4]\], which is consistent with our results. Another study also showed that the SARS-CoV nsp12 has primer-dependent RdRp activity on a synthetic RNA template consisting of a 20-nt duplex and a 5' overhang of 10 uridylates, which could serve as a template during extension of the 20-nt primer \[[@CR34]\]. However, none of the prior studies demonstrated *bona fide* RdRp activity of nsp12, i.e., RNA synthesis initiated *de novo* from exogenous RNA templates and from the 3' ends of viral genomic RNA and its complementary strand. We demonstrated for the first time that the recombinant nsp12 has RNA polymerase activity capable of initiating RNA synthesis *de novo* from the 3' ends of both plus and minus strands of the SARS-CoV genome. This nsp12 could also copy homopolymeric RNA templates in either a primer-independent manner with poly(C) and poly(U) templates or in a primer-dependent manner with poly(A) and poly(G) templates. Our results also suggested that purine nucleotides are preferentially used by nsp12 for *de novo* initiation of RNA synthesis. In contrast, te Velthuis *et al.* \[[@CR34]\] found that the use of poly(U) or poly(C) template did not lead to significant incorporation of nucleotides in RdRp assays with nsp12 with a natural N-terminus and a C-terminal hexahistidine tag. This dramatically different property of nsp12 might be in part attributed to the C-terminal hexahistidine tag.

In contrast to previous data obtained by using recombinant SARS-CoV RdRps \[[@CR4], [@CR34]\], our results also show that nsp12 strictly requires Mn^2+^ ions as a cofactor. Previously, the N-terminal GST-fused SARS-CoV nsp12 showed a primer-dependent RNA polymerase activity in the presence of Mg^2+^ using a poly(A)/oligoU~16~ template \[[@CR4]\]. However, the full-length nsp12 with a C-terminal hexahistidine tag displayed a primer-dependent RNA polymerase activity using a short primed poly(U) template in the presence of either Mg^2+^ or Mn^2+^ \[[@CR33]\]. The authors demonstrated that Mn^2+^ promoted misincorporation of ribonucleotides. The SARS-CoV RTC complex isolated from virus-infected cells displayed RdRp activities *in vitro* only in the presence of Mg^2+^ ions \[[@CR14]\]. The reason for the requirement of different metal ions by the RTC and recombinant nsp12 proteins is not clear. It is possible that the hexahistidine tag or fused proteins at the N- or C-terminus of nsp12 might affect the enzymatic properties of the recombinant nsp12 proteins. Nevertheless, it is worth noting that SARS-CoV nsp8, a second non-canonical RdRp, also requires Mn^2+^ as a cofactor \[[@CR10]\]. Since nsp8 interacts directly with nsp12, as demonstrated by GST pull-down experiments \[[@CR10]\], these two proteins may form a replicase complex showing Mn^2+^ ion dependence for RNA synthesis. It has been argued that Mn^2+^ is unlikely to act as a cofactor of cellular and viral enzymes because Mn^2+^ is known to be present at less than 1 % of the abundance of Mg^2+^ \[[@CR24]\]. However, various enzymes, including viral RdRps, have shown a strict Mn^2+^-dependence \[[@CR24]\]. Mn^2+^-dependent RdRps might overcome the limited availability of Mn^2+^ by their high affinity for Mn^2+^. It is equally plausible to speculate that SARS-CoV nsp12, like other viral RNA polymerases \[[@CR9], [@CR24], [@CR33]\], becomes more error-prone with Mn^2+^. The dependence on Mn^2+^ ions for RdRp activity was also observed for other viral RdRps, including Japanese encephalitis virus NS5 RdRp \[[@CR13]\], equine arteritis virus nsp9 RdRp \[[@CR2]\], RdRps of dengue virus and West Nile virus \[[@CR27]\], and hepatitis C virus NS5B RdRp \[[@CR5], [@CR17], [@CR24]\]. Recent studies showed that HCV NS5B displays different modes of RNA synthesis initiation depending on the types of catalytic metal ions, Mg^2+^ or Mn^2+^; Mn^2+^ appears to stimulate *de novo* RNA synthesis on certain RNA templates \[[@CR24]\].

Stable RNA secondary structures located at the 3' termini of single-stranded RNA viruses play an important role in the initiation of genomic replication \[[@CR8], [@CR16], [@CR20], [@CR22]\]. In addition, the poly(A) tail has been proposed as a potential *cis*-acting element for genome replication and transcription in several viruses \[[@CR15], [@CR31], [@CR32], [@CR36]\]. However, it still remains to be elucidated whether an increase of viral genome abundance after the addition of a poly(A) tail to the 3'-end of viral genomes or defective interfering RNAs was due to the direct effect on viral RNA synthesis rather than to the enhancement of viral gene expression or RNA genome stabilization. Our results demonstrated that the poly(A) tail of the SARS-CoV genome is dispensable for the initiation of minus-strand viral RNA synthesis. Although the SARS-CoV nsp12 required a primer to direct RNA synthesis using a homopolymeric poly(A) template, the tailless 3'-UTR terminal 36-nt served as a template for the *de novo* initiation of RNA synthesis. Thus, the 3'-end RNA structure and/or sequence upstream of the poly(A) tail appears to be the major *cis*-acting element required for initiation of minus-strand RNA synthesis and possibly for discrimination between cellular mRNAs and the viral genomic and subgenomic RNAs. Our data also showed that minus-strand RNA synthesis is inhibited by a poly(A) tail longer than 16 nt, suggesting a regulatory role of the poly(A) in RNA synthesis. Thus, it will be of interest to test whether SARS-CoV genomic and subgenomic RNAs carrying poly(A) tail of different lengths can be differentially utilized by the viral RNA replicase and translational machinery.

Even though the terminal 36-nt of the 3'-UTR allowed nsp12 to carry out *de novo* initiation of RNA synthesis *in vitro*, it remains to be determined whether other viral or cellular proteins are required *in vivo* for the SARS-CoV replicase to recognize specific promoter sequences on the SARS-CoV 3'-UTR. For instance, as proposed recently by Zust *et al.* \[[@CR41]\] for mouse hepatitis virus (MHV) minus-strand RNA synthesis, nsp8 primase of SARS-CoV might bind to a 3'-UTR stem-loop structure and initiate minus-strand RNA synthesis by production of a tract of oligo(U) using the 3'-end poly(A) tail of the viral genome as a template. The authors proposed that the synthesis of a short primer representing the 5' end of minus-strand RNA leads to separation of the 3' end of the genome from pseudoknot loop 1, allowing the formation of a completely folded pseudoknot. That structure, together with nsp8 and other viral nonstructural proteins, then recruits nsp12 to resume elongation of minus-strand RNA synthesis by primer-extension. This notion is in part supported by the fact that the SARS-CoV nsp8 displays an RdRp activity synthesizing a short oligonucleotide \[[@CR10]\]. Thus, nsp8 of SARS-CoV may be required to form a pre-initiation RNA replicase complex through interaction with nsp12 \[[@CR10]\]. Direct binding of an nsp8/nsp12 complex or sequential binding of nsp8 and nsp12 to the 3'-UTR may cooperatively carry out minus-strand RNA synthesis. It would be of interest to investigate whether a short primer generated by the primase activity of nsp8 can be in turn extended by the primer-dependent RNA polymerase activity of nsp12. Furthermore, it should be also noted that coronaviruses, including MHV, bovine coronavirus, and SARS-CoV, have two structurally conserved RNA structures, a bulged stem-loop and an adjacent pseudoknot, upstream of the 3'-UTR \[[@CR7]\]. Genetic studies using a full-length MHV-A59 cDNA cloned into vaccinia virus showed a genetic interaction of the loop 1 of the pseudoknot with the nsp8 and nsp4, which are the components of the RNA replicase \[[@CR41]\]. Since the SARS-CoV 3'-UTR was able to functionally replace its counterpart in the MHV genome, the pseudoknot region might be a critical *cis*-acting element for viral genome replication *in vivo*. Further analysis of the roles of the 3'-UTR and viral or cellular proteins interacting with this *cis*-acting RNA in RNA synthesis initiation is warranted using the *in vitro* RdRp assay system we have established in the present study.

In summary, we have characterized the biochemical properties of a functionally active, full-length SARS-CoV nsp12. The *in vitro* RdRp assay system will be useful for understanding the mechanism of SARS-CoV replication, including how subgenomic viral RNAs are synthesized and what viral and/or host factors are involved in RNA synthesis as cofactors. In addition, the recombinant nsp12 capable of copying the SARS-CoV genome-derived RNA templates will provide a valuable tool for discovery of antiviral drugs against SARS-CoV.

SARS-CoV

:   Severe acute respiratory syndrome coronavirus

RdRp

:   RNA-dependent RNA polymerase

Nsp12

:   Nonstructural protein 12
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